I am not sweating it. Quite the contrary.
The 8K was filed the same time as the agreement with MCET. 7 separate investors each ponied roughly $300,000.
I. Research Agreement Payment Terms:
Due Date Amount
3/10/2015 $225,000
6/1/2015 $225,000
9/1/2015 $225,000
12/1/2015 $225,000
3/1/2016 $225,000
Total $1,125,000
II. License Agreement Payment Terms:
Due Date Amount
3/10/2015 $250,000
4/10/2015 $125,000
5/10/2015 $125,000
Total $500,000
III. Subtotals:
Research Agreement $1,125,000
License Agrement $500,000
Phase 1 - Trial $500,000
Total Payments $2,125,000
8K Total: $2,050,000
Delta: $75,000.00
In my head, I am asking: "What would drive 7 investors to pony up $300k each, close enough to cover the entire cost of both Agreements and then some?"
Could it be possible that OXIS as an SME--through a not so subtle proxy--is working in parallel with an HTA (or two) for a 2nd line treatment for a rare cancer? And if so, does the possibility exist that it is one of the 6 approved for Phase II of the Adaptive Pathways?
Boy, that's too easy. Beautiful, but too easy.
Or could it be that after Phase I applications were shuttered Feb. 28, 2015, OXIS was one of the few asked to retool and resubmit their proposal for Phase II. And IF discussions bare (or bore) fruit, Conditional Marketing Authorization would come next; which, in turn, would give way to limited commercialization.
Of course, that's just the European side. Who knows what might be happening in the States.
And finally, Cataldo could get on the phone and say he gave OXIS everything he could and unfortunately, the technology, the medicine and the science just didn't work.
At $.04 a share, I am along for the ride regardless of the outcome. This is a hot mess that could turn into something special. Something that you and I both know can't be said for at least 95% of all OTC companies.
